@article{6fbb8b4b740f4edf945e3f3d654388b8,
title = "Physical Activity: A Strategy to Improve Antibody Response to a SARS-CoV-2 Vaccine Booster Dose in Patients With Autoimmune Rheumatic Diseases",
abstract = "Background: Physical activity associates with improved immunogenicity following a 2-dose schedule of CoronaVac (Sinovac{\textquoteright}s inactivated SARS-CoV-2 vaccine) in patients with autoimmune rheumatic diseases (ARD). This study evaluates whether physical activity impacts vaccine-induced antibody responses to a booster dose in this population. Methods: This was a phase-4 trial conducted in S{\~a}o Paulo, Brazil. Patients with ARD underwent a 3-dose schedule of CoronaVac. One month after the booster, we assessed seroconversion rates of anti-SARS-CoV-2 S1/S2 IgG, geometric mean titers of anti-S1/S2 IgG, frequency of positive neutralizing antibodies, and neutralizing activity. Physical activity was assessed through questionnaire. Results: Physically active (n = 362) and inactive (n = 278) patients were comparable for most characteristics; however, physically active patients were younger (P < .01) and had a lower frequency of chronic inflammatory arthritis (P < .01). Adjusted models showed that physically active patients had ∼2 times odds of seroconversion rates (OR: 2.09; 95% confidence interval, 1.22 to 3.61), ∼22% greater geometric mean titers of anti-S1/S2 IgG (22.09%; 95% confidence interval, 3.91 to 65.60), and ∼7% greater neutralizing activity (6.76%; 95% confidence interval, 2.80 to 10.72) than inactive patients. Conclusions: Patients with ARD who are physically active have greater odds of experiencing better immunogenicity to a booster dose of CoronaVac. These results support the recommendation of physical activity to improve vaccination responses, particularly for immunocompromised individuals.",
keywords = "COVID-19, immunosuppression, physical inactivity, vaccine responses",
author = "Bruno Gualano and Sieczkowska, {Sofia M.} and Lemes, {{\'I}talo Ribeiro} and {da Silva}, {Rafael Pires} and Pinto, {Ana J.} and Mazzolani, {Bruna C.} and Smaira, {Fabiana I.} and Aikawa, {Nadia E.} and Kupa, {Leonard V.K.} and Pasoto, {Sandra G.} and Medeiros-Ribeiro, {Ana C.} and Saad, {Carla G.S.} and Yuk, {Emily F.N.} and Silva, {Clovis A.} and Paul Swinton and Hallal, {Pedro C.} and Hamilton Roschel and Eloisa Bonfa",
note = "The authors are thankful to Marta H. Lopes, Tatiana Pedrosa, Antonio Jos{\'e} Rodrigues Pereira, Solange Fusco, Priscila Tagliaferro Rojo, and Central Laboratory Division of the Clinical Hospital of the School of Medicine (University of Sao Paulo) for the technical assistance. Author Contributions: Aikawa, Pasoto, Medeiros-Ribeiro, Saad, Yuk, Silva, and Bonfa conceived and designed the study, and supervised clinical data management. Gualano, Lemes, da Silva, Pinto, Mazzolani, Smaira, Sieczkowska, Aikawa, Pasoto, Medeiros-Ribeiro, Saad, Yuk, Silva, Roschel, and Bonfa participated in data collection. Gualano, Lemes, Pinto, Sieczkowska, Swinton, Hallal, and Roschel analyzed and interpreted the data. Gualano, Roschel, and Bonfa wrote the manuscript with inputs from all authors. All authors read and approved the final version. Funding: This trial is sponsored by grants from Funda{\c c}{\~a}o de Amparo {\`a} Pesquisa do Estado de S{\~a}o Paulo (FAPESP) (#2015/03756-4 to Aikawa, Pasoto, Silva, and Bonfa; #2015/26937-4 to Pinto; #2017/13552-2 to Gualano; #2020/ 04877-8 to Lemes; #2017/23688-9 to da Silva; #2019/14820-6 to Mazzolani; #2019/14819-8 to Smaira; and #2019/15231-4 to Sieczkowska), Conselho Nacional de Desenvolvimento Cient{\'i}fico e Tecnol{\'o}gico (CNPq) (#305242/2019-9 to Bonfa and #304984/2020-5 to Silva), Bolsa de Valores do Brasil, and Instituto Todos pela Sa{\'u}de (ITPS 01/2021, C1313 to Bonfa, Silva, Aikawa, and Pasoto) Instituto Butantan supplied the study{\textquoteright}s product and had no other role in the trial. Data availability statement: All background and clinical information for patients with ARD in this study are available from the corresponding author on reasonable request. The authors are thankful to Marta H. Lopes, Tatiana Pedrosa, Antonio Jos{\'e} Rodrigues Pereira, Solange Fusco, Priscila Tagliaferro Rojo, and Central Laboratory Division of the Clinical Hospital of the School of Medicine (University of Sao Paulo) for the technical assistance. Author Contributions: Aikawa, Pasoto, Medeiros-Ribeiro, Saad, Yuk, Silva, and Bonfa conceived and designed the study, and supervised clinical data management. Gualano, Lemes, da Silva, Pinto, Mazzolani, Smaira, Sieczkowska, Aikawa, Pasoto, Medeiros-Ribeiro, Saad, Yuk, Silva, Roschel, and Bonfa participated in data collection. Gualano, Lemes, Pinto, Sieczkowska, Swinton, Hallal, and Roschel analyzed and interpreted the data. Gualano, Roschel, and Bonfa wrote the manuscript with inputs from all authors. All authors read and approved the final version. Funding: This trial is sponsored by grants from Funda{\c c}{\~a}o de Amparo {\`a} Pesquisa do Estado de S{\~a}o Paulo (FAPESP) (#2015/03756-4 to Aikawa, Pasoto, Silva, and Bonfa; #2015/26937-4 to Pinto; #2017/13552-2 to Gualano; #2020/ 04877-8 to Lemes; #2017/23688-9 to da Silva; #2019/14820-6 to Maz-zolani; #2019/14819-8 to Smaira; and #2019/15231-4 to Sieczkowska), Conselho Nacional de Desenvolvimento Cient{\'i}fico e Tecnol{\'o}gico (CNPq) (#305242/2019-9 to Bonfa and #304984/2020-5 to Silva), Bolsa de Valores do Brasil, and Instituto Todos pela Sa{\'u}de (ITPS 01/2021, C1313 to Bonfa, Silva, Aikawa, and Pasoto) Instituto Butantan supplied the study{\textquoteright}s product and had no other role in the trial. Data availability statement: All background and clinical information for patients with ARD in this study are available from the corresponding author on reasonable request.",
year = "2023",
month = apr,
doi = "10.1123/jpah.2022-0332",
language = "English (US)",
volume = "20",
pages = "311--316",
journal = "Journal of Physical Activity and Health",
issn = "1543-3080",
publisher = "Human Kinetics Publishers Inc.",
number = "4",
}